Clinical trial
Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine…
NCT00137774 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00137774 |
|---|---|
| Title | Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors |
| Official title | A Phase II Study of Bevacizumab in Combination With Temozolomide in Patients With Advanced Neuroendocrine Tumors |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Massachusetts General Hospital Beth Israel Deaconess Medical Center Brigham and Women's Hospital Genentech, Inc. Industry Schering-Plough |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neuroendocrine Tumors |
| Intervention type | Drug |
| Interventions | Bevacizumab, Temozolomide |
| Enrollment | 34 |
| Start date | Nov 1, 2004 |
| Primary completion | Jul 1, 2005 |
| Completion | Dec 1, 2012 |
| First posted | Aug 30, 2005 |
| Last update posted | Apr 9, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: